Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aspoxicillin is an injectable, acylaminopenicillin antibiotic synthesized from amoxicillin. It belongs to the penicillin family and exhibits broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria, including some β-lactamase-producing strains. Aspoxicillin is more active than carbenicillin against Pseudomonas aeruginosa but less active than piperacillin against Staphylococcus aureus, Haemophilus influenzae, Enterobacteriaceae, and Pseudomonas aeruginosa. It is not absorbed when administered orally; therefore, it is used via intravenous infusion with a plasma half-life of approximately 87 minutes after IV administration. Clinically, aspoxicillin has been used in the treatment of respiratory tract infections, skin and soft tissue infections, urinary tract infections in adults and children, as well as in combination with aminoglycosides for gynecological infections and infections in patients with hematological disorders[6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspoxicillin.